



If a conflict arises between a Clinical Payment and Coding Policy and any plan document under which a member is entitled to Covered Services, the plan document will govern. If a conflict arises between a CPCP and any provider contract pursuant to which a provider participates in and/or provides Covered Services to eligible member(s) and/or plans, the provider contract will govern. "Plan documents" include, but are not limited to, Certificates of Health Care Benefits, benefit booklets, Summary Plan Descriptions, and other coverage documents. Blue Cross and Blue Shield of New Mexico may use reasonable discretion interpreting and applying this policy to services being delivered in a particular case. BCBSNM has full and final discretionary authority for their interpretation and application to the extent provided under any applicable plan documents.

Providers are responsible for submission of accurate documentation of services performed. Providers are expected to submit claims for services rendered using valid code combinations from Health Insurance Portability and Accountability Act HIPAA approved code sets. Claims should be coded appropriately according to industry standard coding guidelines including, but not limited to: Uniform Billing Editor, American Medical Association, Current Procedural Terminology, CPT® Assistant, Healthcare Common Procedure Coding System, ICD-10 CM and PCS, National Drug Codes, Diagnosis Related Group guidelines, Centers for Medicare and Medicaid Services National Correct Coding Initiative Policy Manual, CCI table edits and other CMS guidelines.

Claims are subject to the code edit protocols for services/procedures billed. Claim submissions are subject to claim review including but not limited to, any terms of benefit coverage, provider contract language, medical policies, clinical payment and coding policies as well as coding software logic. Upon request, the provider is urged to submit any additional documentation.

## Testing of Homocysteine Metabolism-Related Conditions

**Policy Number:** CPCPLAB067

**Version 1.0**

**Approval Date:** Jan. 12, 2026

**Plan Effective Date:** May 1, 2026

## Description

The Plan has implemented certain lab management reimbursement criteria. Not all requirements apply to each product. Providers are urged to review Plan documents for eligible coverage for services rendered.

## Reimbursement Information:

1. Newborn screening for homocysteine-related conditions **may be reimbursable** in any of the following situations:
  - a. Screening for classic homocystinuria due to cystathionine  $\beta$ -synthase (CBS) deficiency by performing quantitative plasma amino acids analysis and/or plasma or urine total homocysteine analysis.
  - b. Screening for homocystinuria in dried blood spots.
  - c. Screening for hypermethioninemia in dried blood spots.
2. When the initial screening test result exceeds the cut-off level of methionine, a repeat dried blood specimen submitted to the newborn screening program, or a quantitative plasma amino acid analysis and analysis of plasma total homocysteine **may be reimbursable**.
3. For individuals over 18 years of age with homocystinuria suspected to be caused by CBS deficiency and for monitoring therapy in those with confirmed CBS, total homocysteine testing in plasma **may be reimbursable**.
4. Plasma free homocysteine testing **is not reimbursable**.

## Procedure Codes

The following is not an all-encompassing code list. The inclusion of a code does not guarantee that it is a covered service or eligible for reimbursement.

Codes
82136, 82139, 82615, 83090, 83921

## References:

1. NIH. Homocystinuria due to CBS deficiency.  
<https://rarediseases.info.nih.gov/diseases/6667/homocystinuria-due-to-cbs-deficiency>
2. Mudd SH, Finkelstein JD, Refsum H, et al. Homocysteine and its disulfide derivatives: a suggested consensus terminology. *Arteriosclerosis, thrombosis, and vascular biology*. Jul 2000;20(7):1704-6.

3. Zhu H, Blake S, Chan KT, Pearson RB, Kang J. Cystathionine beta-Synthase in Physiology and Cancer. *BioMed research international*. 2018;2018:3205125. doi:10.1155/2018/3205125
4. Mazaheri, Mostofizadeh, Hashemipour. Homocystinuria with Stroke and Positive Familial History. *Adv Biomed Res*. 2017;
5. Li, Barshop, Feigenbaum, Khanna. Brain Magnetic Resonance Imaging Findings in Poorly Controlled Homocystinuria. *J Radiol Case Rep*. 2018;
6. Ismayilova N, MacKinnon AD, Mundy H, Fallon P. Reversible Cerebral White Matter Abnormalities in Homocystinuria. *JIMD Rep*. 2019;44:115-119. doi:10.1007/8904\_2018\_135
7. Mudd SH, Skovby F, Levy HL, et al. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. *American journal of human genetics*. Jan 1985;37(1):1-31.
8. Gaustadnes M, Ingerslev J, Rütiger N. Prevalence of Congenital Homocystinuria in Denmark. *New England Journal of Medicine*. 1999/05/13 1999;340(19):1513-1513. doi:10.1056/NEJM199905133401915
9. Janosík M, Sokolová J, Janosíková B, Krijt J, Klatovská V, Kozich V. Birth prevalence of homocystinuria in Central Europe: frequency and pathogenicity of mutation c.1105C>T (p.R369C) in the cystathionine beta-synthase gene. *The Journal of pediatrics*. 2009;154(3):431-437. doi:10.1016/j.jpeds.2008.09.015
10. Al-Sadeq DW, Nasrallah GK. The Spectrum of Mutations of Homocystinuria in the MENA Region. *Genes (Basel)*. Mar 20 2020;11(3)doi:10.3390/genes11030330
11. Rosenson RS, Smith CC, Bauer KA. Overview of homocysteine. Updated January 24, 2025. <https://www.uptodate.com/contents/overview-of-homocysteine>
12. Abbott MH, Folstein SE, Abbey H, Pyeritz RE. Psychiatric manifestations of homocystinuria due to cystathionine beta-synthase deficiency: prevalence, natural history, and relationship to neurologic impairment and vitamin B6-responsiveness. *American journal of medical genetics*. Apr 1987;26(4):959-69. doi:10.1002/ajmg.1320260427
13. Rose NC, Dolan SM. Newborn screening and the obstetrician. *Obstetrics and gynecology*. 2012;120(4):908-917. doi:10.1097/AOG.0b013e31826b2f03
14. Sacharow SJ, Picker JD, Levy HL. Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency. In: Adam MP, Ardinger HH, Pagon RA, et al, eds. *GeneReviews((R))*. University of Washington, Seattle; 2004.
15. Froese DS, Kopec J, Fitzpatrick F, et al. Structural Insights into the MMACHC-MMADHC Protein Complex Involved in Vitamin B12 Trafficking. *The Journal of biological chemistry*. Dec 4 2015;290(49):29167-77. doi:10.1074/jbc.M115.683268
16. Wang W, Jiao XH, Wang XP, Sun XY, Dong C. MTR, MTRR, and MTHFR Gene Polymorphisms and Susceptibility to Nonsyndromic Cleft Lip With or Without Cleft Palate. *Genetic testing and molecular biomarkers*. Jun 2016;20(6):297-303. doi:10.1089/gtmb.2015.0186
17. Collison FT, Xie YA, Gambin T, et al. Whole Exome Sequencing Identifies an Adult-Onset Case of Methylmalonic Aciduria and Homocystinuria Type C (cblC) with Non-Syndromic Bull's Eye Maculopathy. *Ophthalmic Genet*. 2015;36(3):270-5. doi:10.3109/13816810.2015.1010736
18. Nelson BC, Pfeiffer CM, Sniegoski LT, Satterfield MB. Development and evaluation of an isotope dilution LC/MS method for the determination of total homocysteine in human plasma. *Analytical chemistry*. Feb 15 2003;75(4):775-84.

19. Belkhiria MN, Ducros V, Harzallah K, et al. [Evaluation of plasmatic homocysteine determination by gas chromatography-mass spectrometry]. *Annales de biologie clinique*. Jul-Aug 2007;65(4):393-8. Evaluation d'un transfert de methode : dosage de l'homocysteine plasmatique par chromatographie en phase gazeuse couplee a la spectrometrie de masse.
20. Nexo E, Engbaek F, Ueland PM, et al. Evaluation of Novel Assays in Clinical Chemistry: Quantification of Plasma Total Homocysteine. *Clinical Chemistry*. 2000;46(8):1150.
21. Concepción-Alvarez A, Camayd-Viera I, Nuevas-Paz L. Validation of an HPLC method for total homocysteine quantification in plasma. *Revista del Laboratorio Clinico*. 2016;9(2):40-47. doi:10.1016/j.labcli.2016.02.003
22. de Sain-van der Velden MGM, van der Ham M, Jans JJ, et al. Suitability of methylmalonic acid and total homocysteine analysis in dried bloodspots. *Anal Chim Acta*. Jan 1 2015;853:435-441. doi:10.1016/j.aca.2014.10.043
23. Long S, Goldblatt J. MTHFR genetic testing: Controversy and clinical implications. *Australian Family Physician*. 4/01 2016;45:237-240.
24. Gonzales MC, Yu P, Shiao SPK. MTHFR Gene Polymorphism-Mutations and Air Pollution as Risk Factors for Breast Cancer: A Metaprediction Study. *Nursing research*. 2017;66(2):152-163. doi:10.1097/NNR.0000000000000206
25. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. *Nature genetics*. May 1995;10(1):111-3. doi:10.1038/ng0595-111
26. Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. *Molecular genetics and metabolism*. Jul 1998;64(3):169-72. doi:10.1006/mgme.1998.2714
27. Kluijtmans LA, Young IS, Boreham CA, et al. Genetic and nutritional factors contributing to hyperhomocysteinemia in young adults. *Blood*. Apr 1 2003;101(7):2483-8. doi:10.1182/blood.V101.7.2483
28. Harmon DL, Shields DC, Woodside JV, et al. Methionine synthase D919G polymorphism is a significant but modest determinant of circulating homocysteine concentrations. *Genetic epidemiology*. Nov 1999;17(4):298-309. doi:10.1002/(sici)1098-2272(199911)17:4<298::Aid-gepi5>3.0.co;2-v
29. Gaughan DJ, Kluijtmans LA, Barbaux S, et al. The methionine synthase reductase (MTRR) A66G polymorphism is a novel genetic determinant of plasma homocysteine concentrations. *Atherosclerosis*. Aug 2001;157(2):451-6.
30. Gales A, Masingue M, Millecamps S, et al. Adolescence/adult onset MTHFR deficiency may manifest as isolated and treatable distinct neuro-psychiatric syndromes. *Orphanet J Rare Dis*. Feb 1 2018;13(1):29. doi:10.1186/s13023-018-0767-9
31. Okun JG, Gan-Schreier H, Ben-Omran T, et al. Newborn Screening for Vitamin B6 Non-responsive Classical Homocystinuria: Systematical Evaluation of a Two-Tier Strategy. *JIMD Rep*. 2017;32:87-94. doi:10.1007/8904\_2016\_556
32. Guo Q-n, Wang L, Liu Z-y, et al. Different effects of maternal homocysteine concentration, MTHFR and MTRR genetic polymorphisms on the occurrence of fetal aneuploidy. *Reproductive BioMedicine Online*. 2022/12/01/ 2022;45(6):1207-1215. doi:10.1016/j.rbmo.2022.06.024

33. HHS. Recommended Uniform Screening Panel. Updated July, 2024.  
<https://www.hrsa.gov/advisory-committees/heritable-disorders/rusp/index.html>

34. ACMG. Newborn Screening ACT Sheet [Increased Methionine] Homocystinuria (CBS Deficiency) Updated December, 2021.  
<https://www.acmg.net/PDFLibrary/Methionine.pdf>

35. ACMG. Methionine Elevated or Decreased. American College of Medical Genetics and Genomics. Updated December, 2021.  
<http://www.acmg.net/PDFLibrary/Methionine-Algorithm.pdf>

36. Huemer M, Kožich V, Rinaldo P, et al. Newborn screening for homocystinurias and methylation disorders: systematic review and proposed guidelines. *Journal of inherited metabolic disease*. 2015;38(6):1007-1019. doi:10.1007/s10545-015-9830-z

37. Huemer M, Diodato D, Schwahn B, et al. Guidelines for diagnosis and management of the cobalamin-related remethylation disorders cblC, cblD, cblE, cblF, cblG, cblJ and MTHFR deficiency. *J Inherit Metab Dis*. 2017;40(1):21-48. doi:10.1007/s10545-016-9991-4

38. Morris AAM, Kožich V, Santra S, et al. Guidelines for the diagnosis and management of cystathione beta-synthase deficiency. journal article. January 01 2017;40(1):49-74. doi:10.1007/s10545-016-9979-0

39. FDA. Invader MTHFR 677 510(k) Summary. 2021. Updated May 13, 2011.  
[https://www.accessdata.fda.gov/cdrh\\_docs/pdf10/K100987.pdf](https://www.accessdata.fda.gov/cdrh_docs/pdf10/K100987.pdf)

40. FDA. Invader MTHFR 1298 510(k) Summary. 2021. Updated April 25, 2011.  
[https://www.accessdata.fda.gov/cdrh\\_docs/pdf10/K100496.pdf](https://www.accessdata.fda.gov/cdrh_docs/pdf10/K100496.pdf)

41. FDA. eSensor Thrombophilia Risk Test on XT-8 System. Updated March 24, 2010.  
[https://www.accessdata.fda.gov/cdrh\\_docs/pdf9/K093974.pdf](https://www.accessdata.fda.gov/cdrh_docs/pdf9/K093974.pdf)

42. FDA. Nanosphere 510(k) Summary. Updated October 11, 2007.  
[https://www.accessdata.fda.gov/cdrh\\_docs/pdf7/K070597.pdf](https://www.accessdata.fda.gov/cdrh_docs/pdf7/K070597.pdf)

## Policy Update History:

Approval Date	Effective Date; Summary of Revisions
01/12/2026	05/01/2026; Document updated with literature review. The following change was made to Reimbursement Information: removed #3 as it is considered a medical procedure and not a laboratory test "For the diagnosis of phenotype variants of classic homocystinuria due to CBS deficiency, the pyridoxine (B6) challenge test may be reimbursable." Removed code 84207. References revised.
01/23/2025	04/15/2025; Document updated with literature review. Reimbursement Information unchanged. References revised.
03/15/2024	Document updated with literature review. Reimbursement Information unchanged. References revised; one new reference added.
11/01/2023	Document updated with literature review. Reimbursement information revised for clarity. References revised.
05/01/2022	New policy